Through a new partnership, Caris will use its comprehensive genomic profiling tests to sequence more than 10,000 early-stage breast tumors collected in TAILORx.
NEW YORK – Cancer Research UK and Australian charity the Minderoo Foundation said on Wednesday they are collectively committing approximately £3.4 million (about $4.4 million) to fund an adaptive ...
The strategic shift will allow the firm to focus on advancing a newly announced in vivo gene-editing therapy candidate that's in preclinical development.
The companies will study genetic associations linked to autoimmune diseases to identify target genes as well as patients most likely to respond to therapy.